U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095686) titled 'Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS' on May 12.
Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Study Start Date: Oct. 02, 2024
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
DRUG: nL-CHCHD-001
Personalized antisense oligonucleotide
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: n-Lorem Foundation
Published by HT Digital Content Services with permission from Health Daily D...